An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants

Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma

Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)